AVR

Business Context and Reporting Period

Company: Anteris Technologies Global Corp. (AVR)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and nine months ended September 30, 2025
Business Overview: Anteris is a structural heart company developing the DurAVR® Transcatheter Heart Valve (THV) System using proprietary ADAPT® tissue-enhancing technology. The company operates as a single segment focused on the development and commercialization of this system. It is classified as an Emerging Growth Company and a Smaller Reporting Company.

Key Financial Metrics

Note: Debt obligations consist of $96k current and $26k long-term. Cash balance decreased significantly from $70.5 million at year-end 2024 to $9.1 million at September 30, 2025.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 44% in Q3 and 26% in the nine-month period compared to 2024. This is primarily due to the expiration of the Transition Services Agreement with LeMaitre in January 2025, which previously generated sales of CardioCel® and VascuCel® products.
• Increased R&D Spend: R&D expenses rose 21% in Q3 and 30% in the nine-month period. Increases were driven by upscaling manufacturing and quality capabilities, preparatory activities for the PARADIGM Trial, and headcount expansion, partially offset by reduced product research costs as focus shifts to clinical trials.
• SG&A Reduction: Selling, general, and administrative expenses decreased 17% in Q3 and 16% in the nine-month period, largely due to lower share-based payment expenses and reduced legal/compliance costs compared to the IPO-related expenses in 2024.
• Cash Burn: Net cash used in operating activities increased 38% year-over-year for the nine-month period to $59.3 million, reflecting higher operational and clinical trial costs.

Guidance, Outlook, and Risks

• Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern for one year from the issuance date. The company anticipates needing additional capital to fund operations and complete the PARADIGM Trial.
• Recent Capital Raise (Subsequent Event): In October and November 2025, the company completed a private placement generating gross proceeds of approximately $25.2 million. This transaction closed after the balance sheet date.
• Clinical Progress: The company received FDA approval in early November 2025 to initiate the PARADIGM Trial. The first European regulatory clearance was received in Denmark in October 2025, and the first patients were enrolled.
• Internal Controls: Management identified material weaknesses in internal control over financial reporting related to a lack of documented procedures and segregation of duties. These remain unremediated as of September 30, 2025, though a remediation plan is in progress.
• Regulatory Risks: Success depends on obtaining Premarket Approval (PMA) from the FDA and CE Mark approval. There is no guarantee the PARADIGM Trial will be successful or that approvals will be granted.

Key Facts for Investor Verification

• Liquidity Position: Verify the impact of the $25.2 million private placement (closed post-period) on the company's runway, given the cash balance of only $9.1 million at period end.
• Revenue Sustainability: Confirm the status of the agreement with 4C Medical Technologies, Inc., as the LeMaitre agreement has expired and revenue is now heavily reliant on 4C.
• Internal Control Remediation: Monitor the progress of the remediation plan for material weaknesses in internal controls, which currently render disclosure controls ineffective.
• Trial Milestones: Track enrollment rates and interim data from the PARADIGM Trial, which is critical for future FDA PMA and commercialization.
• Dilution Impact: Note that the subsequent issuance of shares and warrants will materially impact loss per share calculations in future periods.